

5-3-2013

To,
The Manager,
Department of Corporate Services,
Bombay Stock Exchange Limited
P. J. Towers, Dalal Street,
Fort, Mumbai

**Sub: Press Release: Alembic Receives USFDA Approval for its NDA –
Desvenlafaxine Base Extended Release Tablets.**

Dear Sir,

With reference to the captioned matter, we enclose herewith a press release dated 5th March, 2013 captioned Alembic Receives USFDA Approval for its NDA – Desvenlafaxine Base Extended Release Tablets and Enters into an out-licensing agreement with Ranbaxy to market the product in USA.

Kindly take note of the same.

Thanking you,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director-Finance
& Company Secretary

Encl.: A/a

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : (0265) 2280550, 2280880, • FAX : (0265) 2282506
www.alembic-india.com • E-mail : alembic@alembic.co.in

5-3-2013

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra-Kurla Complex,
Bandra – East,
Mumbai


**Sub: Press Release: Alembic Receives USFDA Approval for its NDA –
Desvenlafaxine Base Extended Release Tablets.**

Dear Sir,

With reference to the captioned matter, we enclose herewith a press release dated 5th March, 2013 captioned Alembic Receives USFDA Approval for its NDA – Desvenlafaxine Base Extended Release Tablets and Enters into an out-licensing agreement with Ranbaxy to market the product in USA.

Kindly take note of the same.

Thanking you,
For **Alembic Pharmaceuticals Limited**


R. K. Baheti
Director-Finance
& Company Secretary

Encl.: A/a

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : (0265) 2280550, 2280880, • FAX : (0265) 2282506
www.alembic-india.com • E-mail : alembic@alembic.co.in

PRESS RELEASE

March 5, 2013

Alembic Receives USFDA Approval for its NDA - Desvenlafaxine Base Extended Release Tablets.

Enters into an out-licensing agreement with Ranbaxy to market the product in USA

Vadodara, March 5, 2013 - Alembic Pharmaceuticals Limited announced today that the company has received approval from the US FDA for its NDA, Desvenlafaxine Base Extended Release Tablets, a bioequivalent version of innovator drug, Pristiq® by Pfizer. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the NDA. Desvenlafaxine Base Extended Release Tablets is Alembic's first 505 (b)(2) filing.

The company has entered into an out-licensing arrangement with Ranbaxy Pharmaceuticals Inc. (Ranbaxy), a wholly owned subsidiary of Ranbaxy Laboratories Limited for exclusively marketing the product in the United States of America. The product will be available in 50 mg and 100 mg dosage strengths. The parties will launch the product immediately.

Desvenlafaxine base Extended Release Tablets is a prescription medicine that is indicated for the treatment of major depressive disorder. The current market size for Pristiq is approximately US\$538Mn, based on industry sales data.

About Alembic:

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 3000 sales representatives, are well recognized by doctors and patients. More information about the company can be found at www.alembic-india.com; (Reuters: ALEM.NS, Bloomberg: ALPM:IN, NSE: APLTD, BSE: 533573)

About Ranbaxy:

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited, India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880, • FAX : (0265) 2282506
www.alembic-india.com • E-mail : alembic@alembic.co.in

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 43 countries and manufacturing operations in 8 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com

For further information, please contact:

Mitanshu Shah

Phone: +91 265 3007630

Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : (0265) 2280550, 2280880, • FAX : (0265) 2282506
www.alembic-india.com • E-mail : alembic@alembic.co.in